Subscribe to Entrepreneur for $5

What's in Store for Teladoc Health's (TDOC) Earnings in Q3?

Teladoc Health (TDOC) is likely to report a strong revenue outperformance for the third quarter, driven by broad-based momentum across its business and a sharp acceleration in visit-volume growth.

This story originally appeared on Zacks

Teladoc Health, Inc. TDOC is scheduled to release third-quarter 2021 results on Oct 27, 2021, after the market closes.

- Zacks

Q3 Earnings & Revenue Expectations

The Zacks Consensus Estimate for Teladoc Health’s third-quarter loss of 63 cents per share indicates a deterioration from the loss of 13 cents reported in the year-ago quarter. The consensus estimate for sales of $516.66 million suggests a 78.89% rise from the year-ago period’s reported figure.

Factors to Note

Revenues are likely to have gained from higher Access Fee revenues. The increase in access fee revenues might have been primarily led by the acquisitions of Livongo and InTouch Health, both of which generate a chunk of revenues from subscription access fees as well as growth in direct-to-consumer mental health, which is sold on a subscription basis.

Total expenses are expected to have escalated in the quarter, primarily due to higher advertising and marketing, sales, technology and development, legal and regulatory, acquisition and integration-related costs as well as general and administrative expenses.

For the to-be-reported quarter, the company anticipates total visits in the range of 3.4-3.6 million. Total paid membership is projected between 52 million and 53 million members. Visit-fee-only access members are envisioned to be approximately 22 million individuals.

Earnings Surprise History

The company’s bottom line beat estimates in two of the last four quarters (missing the mark on the remaining two occasions), the average surprise being 32.42%.

Teladoc Health, Inc. Price and EPS Surprise Teladoc Health, Inc. Price and EPS Surprise

Teladoc Health, Inc. price-eps-surprise | Teladoc Health, Inc. Quote

What Our Model Says

Our proven model does not predict an earnings beat for Teladoc Health this time around. The combination of a positive   Earnings ESP  and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. But this is not the case here as elaborated below.

Earnings ESP:  Teladoc Health has an Earnings ESP of 0.00%.

Zacks Rank:  Teladoc Health currently carries a Zacks Rank #3. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

You can see the complete list of today’s Zacks #1 Rank stocks here.

Stocks to Consider

Here are some stocks worth considering from the medical space with the perfect mix of elements to surpass estimates in their upcoming releases.

Molina Healthcare, Inc. MOH has an Earnings ESP of +0.40% and is Zacks #3 Ranked, currently.

Pfizer Inc. PFE has an Earnings ESP of +2.20% and a Zacks Rank #2 at present.

Eli Lilly and Company LLY has an Earnings ESP of +0.76% and a Zacks Rank of 3, currently.



Infrastructure Stock Boom to Sweep America

A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.

The only question is “Will you get into the right stocks early when their growth potential is greatest?”

Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.

Download FREE: How to Profit from Trillions on Spending for Infrastructure >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


Pfizer Inc. (PFE): Free Stock Analysis Report


Eli Lilly and Company (LLY): Free Stock Analysis Report


Molina Healthcare, Inc (MOH): Free Stock Analysis Report


Teladoc Health, Inc. (TDOC): Free Stock Analysis Report


To read this article on click here.


Zacks Investment Research